Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer

BACKGROUND: Erlotinib, the epidermal growth factor receptor tyrosine kinase inhibitor, and the intra-venous vinflunine vinca alkaloid microtubule inhibitor have been shown to be effective in the setting of non-small-cell lung cancer (NSCLC) palliative patients with acceptable toxicities. This phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzakowski, M., Bennouna, J., Dansin, E., Kowalski, D., Hiret, S., Penel, N., Favrel, S., Tourani, J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909260/
https://www.ncbi.nlm.nih.gov/pubmed/24220936
http://dx.doi.org/10.1007/s00280-013-2342-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909260/
https://www.ncbi.nlm.nih.gov/pubmed/24220936
http://dx.doi.org/10.1007/s00280-013-2342-3

Ejemplares similares